| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 34 | 2021 | 3035 | 5.450 |
Why?
|
| Medical Oncology | 19 | 2022 | 382 | 5.220 |
Why?
|
| Colorectal Neoplasms | 32 | 2024 | 981 | 4.580 |
Why?
|
| Healthcare Disparities | 11 | 2019 | 410 | 2.900 |
Why?
|
| Colonic Neoplasms | 14 | 2022 | 573 | 2.250 |
Why?
|
| Drug Costs | 5 | 2020 | 63 | 2.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 27 | 2024 | 2552 | 1.820 |
Why?
|
| Patient Care Bundles | 3 | 2018 | 20 | 1.740 |
Why?
|
| Health Care Costs | 5 | 2019 | 235 | 1.610 |
Why?
|
| Rectal Neoplasms | 9 | 2024 | 127 | 1.560 |
Why?
|
| Health Care Reform | 5 | 2015 | 85 | 1.520 |
Why?
|
| Spiritual Therapies | 2 | 2021 | 4 | 1.510 |
Why?
|
| Adenocarcinoma | 15 | 2024 | 1194 | 1.480 |
Why?
|
| Health Equity | 2 | 2023 | 94 | 1.410 |
Why?
|
| United States | 35 | 2022 | 6957 | 1.350 |
Why?
|
| Antineoplastic Agents | 12 | 2021 | 2412 | 1.350 |
Why?
|
| National Cancer Institute (U.S.) | 3 | 2017 | 73 | 1.310 |
Why?
|
| Peritoneal Neoplasms | 7 | 2023 | 184 | 1.240 |
Why?
|
| Medicare | 9 | 2022 | 423 | 1.240 |
Why?
|
| Humans | 120 | 2024 | 89073 | 1.230 |
Why?
|
| Appendiceal Neoplasms | 6 | 2023 | 31 | 1.210 |
Why?
|
| Hyperthermia, Induced | 6 | 2023 | 73 | 1.200 |
Why?
|
| Delivery of Health Care | 6 | 2021 | 435 | 1.180 |
Why?
|
| Advance Care Planning | 2 | 2018 | 43 | 1.160 |
Why?
|
| Minority Groups | 4 | 2017 | 144 | 1.120 |
Why?
|
| Religion | 2 | 2018 | 88 | 1.110 |
Why?
|
| Reimbursement Mechanisms | 6 | 2019 | 41 | 1.100 |
Why?
|
| Health Literacy | 2 | 2019 | 72 | 1.080 |
Why?
|
| Clinical Trials as Topic | 6 | 2019 | 1149 | 1.080 |
Why?
|
| Societies, Medical | 4 | 2018 | 570 | 1.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2020 | 531 | 1.000 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 359 | 0.980 |
Why?
|
| Stomach Neoplasms | 7 | 2024 | 281 | 0.930 |
Why?
|
| Patient Participation | 3 | 2022 | 224 | 0.850 |
Why?
|
| Survival Analysis | 5 | 2020 | 1533 | 0.830 |
Why?
|
| Middle Aged | 52 | 2024 | 25865 | 0.790 |
Why?
|
| Terminal Care | 2 | 2021 | 137 | 0.790 |
Why?
|
| Models, Economic | 3 | 2019 | 62 | 0.780 |
Why?
|
| Hockey | 1 | 2021 | 9 | 0.750 |
Why?
|
| American Cancer Society | 2 | 2017 | 13 | 0.740 |
Why?
|
| Insurance, Health, Reimbursement | 3 | 2016 | 60 | 0.730 |
Why?
|
| Aged | 49 | 2024 | 19078 | 0.720 |
Why?
|
| Male | 58 | 2024 | 42254 | 0.710 |
Why?
|
| Female | 61 | 2024 | 46014 | 0.680 |
Why?
|
| Urban Population | 2 | 2018 | 224 | 0.680 |
Why?
|
| Periodicals as Topic | 2 | 2019 | 168 | 0.670 |
Why?
|
| Racism | 1 | 2021 | 89 | 0.670 |
Why?
|
| Insurance, Health | 2 | 2021 | 159 | 0.670 |
Why?
|
| Multimedia | 1 | 2019 | 9 | 0.670 |
Why?
|
| Breast Neoplasms | 8 | 2022 | 3000 | 0.670 |
Why?
|
| Health Expenditures | 2 | 2018 | 91 | 0.670 |
Why?
|
| Prognosis | 11 | 2023 | 3773 | 0.660 |
Why?
|
| Social Justice | 1 | 2019 | 54 | 0.630 |
Why?
|
| Medicaid | 3 | 2017 | 229 | 0.610 |
Why?
|
| Health Personnel | 1 | 2020 | 212 | 0.600 |
Why?
|
| Organizational Objectives | 1 | 2017 | 24 | 0.600 |
Why?
|
| Fluorouracil | 15 | 2024 | 561 | 0.600 |
Why?
|
| Social Class | 3 | 2021 | 135 | 0.590 |
Why?
|
| Patient Care Team | 1 | 2020 | 283 | 0.590 |
Why?
|
| Glucuronosyltransferase | 4 | 2020 | 186 | 0.590 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2024 | 967 | 0.590 |
Why?
|
| Health Status Disparities | 3 | 2020 | 187 | 0.580 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2017 | 67 | 0.580 |
Why?
|
| Metformin | 2 | 2018 | 124 | 0.570 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 160 | 0.560 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2017 | 315 | 0.560 |
Why?
|
| Health Services Misuse | 1 | 2016 | 19 | 0.560 |
Why?
|
| Health Services Research | 1 | 2017 | 137 | 0.560 |
Why?
|
| Neuroendocrine Tumors | 3 | 2024 | 117 | 0.560 |
Why?
|
| Quality of Health Care | 3 | 2017 | 385 | 0.550 |
Why?
|
| Biomedical Research | 2 | 2017 | 398 | 0.540 |
Why?
|
| Health Policy | 2 | 2014 | 184 | 0.530 |
Why?
|
| Internal-External Control | 1 | 2016 | 45 | 0.530 |
Why?
|
| Critical Pathways | 1 | 2016 | 37 | 0.530 |
Why?
|
| Bevacizumab | 8 | 2022 | 287 | 0.520 |
Why?
|
| Aged, 80 and over | 24 | 2024 | 6777 | 0.510 |
Why?
|
| Mortality, Premature | 1 | 2015 | 4 | 0.500 |
Why?
|
| Precision Medicine | 3 | 2018 | 410 | 0.500 |
Why?
|
| Physicians | 2 | 2020 | 689 | 0.490 |
Why?
|
| Survival Rate | 12 | 2023 | 1889 | 0.480 |
Why?
|
| Neoplasm Staging | 14 | 2023 | 2001 | 0.480 |
Why?
|
| Chemoprevention | 1 | 2014 | 92 | 0.470 |
Why?
|
| Heart Arrest | 1 | 2017 | 279 | 0.450 |
Why?
|
| Ambulatory Care | 1 | 2015 | 187 | 0.440 |
Why?
|
| Leucovorin | 11 | 2024 | 224 | 0.430 |
Why?
|
| Intensive Care Units | 1 | 2016 | 395 | 0.430 |
Why?
|
| Treatment Outcome | 23 | 2024 | 8203 | 0.410 |
Why?
|
| Hospitalization | 2 | 2016 | 876 | 0.410 |
Why?
|
| Health Services Accessibility | 5 | 2020 | 424 | 0.410 |
Why?
|
| Pancreatic Neoplasms | 4 | 2024 | 667 | 0.400 |
Why?
|
| Mass Screening | 7 | 2021 | 636 | 0.400 |
Why?
|
| Intestinal Neoplasms | 2 | 2024 | 64 | 0.400 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 348 | 0.400 |
Why?
|
| Cytoreduction Surgical Procedures | 8 | 2023 | 76 | 0.400 |
Why?
|
| Palliative Care | 3 | 2023 | 263 | 0.400 |
Why?
|
| Socioeconomic Factors | 6 | 2020 | 582 | 0.390 |
Why?
|
| Patient Care | 1 | 2012 | 102 | 0.380 |
Why?
|
| Early Detection of Cancer | 5 | 2021 | 415 | 0.370 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 377 | 0.360 |
Why?
|
| Adult | 30 | 2024 | 26508 | 0.360 |
Why?
|
| Spirituality | 2 | 2021 | 87 | 0.350 |
Why?
|
| Anus Neoplasms | 2 | 2022 | 36 | 0.350 |
Why?
|
| Algorithms | 1 | 2018 | 1875 | 0.340 |
Why?
|
| Combined Modality Therapy | 9 | 2024 | 1710 | 0.340 |
Why?
|
| Camptothecin | 5 | 2022 | 193 | 0.340 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2024 | 665 | 0.330 |
Why?
|
| Costs and Cost Analysis | 3 | 2022 | 153 | 0.330 |
Why?
|
| Liver Neoplasms | 4 | 2023 | 754 | 0.330 |
Why?
|
| Retrospective Studies | 16 | 2023 | 9003 | 0.330 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 174 | 0.320 |
Why?
|
| Surveys and Questionnaires | 6 | 2020 | 2612 | 0.320 |
Why?
|
| Antibodies, Monoclonal | 5 | 2021 | 1401 | 0.320 |
Why?
|
| Prospective Studies | 10 | 2022 | 4273 | 0.310 |
Why?
|
| SEER Program | 2 | 2006 | 197 | 0.310 |
Why?
|
| Esophageal Neoplasms | 3 | 2020 | 332 | 0.310 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2019 | 111 | 0.310 |
Why?
|
| Receptor, ErbB-2 | 1 | 2010 | 245 | 0.300 |
Why?
|
| Receptors, Estrogen | 1 | 2010 | 393 | 0.300 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 738 | 0.300 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 3657 | 0.300 |
Why?
|
| Income | 2 | 2019 | 83 | 0.300 |
Why?
|
| Disease-Free Survival | 9 | 2022 | 1214 | 0.290 |
Why?
|
| Decision Making | 3 | 2018 | 665 | 0.290 |
Why?
|
| Government Regulation | 2 | 2019 | 49 | 0.280 |
Why?
|
| Forecasting | 2 | 2017 | 305 | 0.270 |
Why?
|
| Incidence | 4 | 2017 | 1592 | 0.270 |
Why?
|
| Organoplatinum Compounds | 6 | 2018 | 97 | 0.270 |
Why?
|
| Clinical Decision-Making | 3 | 2018 | 280 | 0.260 |
Why?
|
| Thromboembolism | 1 | 2006 | 120 | 0.250 |
Why?
|
| Case-Control Studies | 4 | 2017 | 1855 | 0.250 |
Why?
|
| X-linked Nuclear Protein | 1 | 2024 | 9 | 0.240 |
Why?
|
| Co-Repressor Proteins | 1 | 2024 | 24 | 0.240 |
Why?
|
| Receptors, Peptide | 1 | 2024 | 22 | 0.240 |
Why?
|
| Decision Support Techniques | 2 | 2016 | 167 | 0.240 |
Why?
|
| Octreotide | 2 | 2024 | 23 | 0.240 |
Why?
|
| Cohort Studies | 9 | 2023 | 2863 | 0.240 |
Why?
|
| Risk Factors | 7 | 2017 | 5466 | 0.240 |
Why?
|
| Capecitabine | 3 | 2022 | 98 | 0.230 |
Why?
|
| Neoadjuvant Therapy | 4 | 2024 | 373 | 0.230 |
Why?
|
| Molecular Chaperones | 1 | 2024 | 122 | 0.230 |
Why?
|
| Chicago | 5 | 2020 | 1423 | 0.230 |
Why?
|
| Pharmacogenetics | 2 | 2018 | 443 | 0.230 |
Why?
|
| Surgical Oncology | 1 | 2023 | 27 | 0.220 |
Why?
|
| Benzimidazoles | 1 | 2024 | 111 | 0.220 |
Why?
|
| Databases, Factual | 3 | 2019 | 850 | 0.220 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 250 | 0.220 |
Why?
|
| Appendix | 1 | 2023 | 31 | 0.220 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 47 | 0.210 |
Why?
|
| Neoplasms, Second Primary | 2 | 2024 | 260 | 0.200 |
Why?
|
| Mutation | 4 | 2024 | 4132 | 0.200 |
Why?
|
| Neoplasm Metastasis | 5 | 2019 | 1108 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2021 | 859 | 0.200 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2006 | 435 | 0.200 |
Why?
|
| Cost-Benefit Analysis | 4 | 2019 | 461 | 0.190 |
Why?
|
| Cetuximab | 3 | 2017 | 117 | 0.190 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 848 | 0.190 |
Why?
|
| Qualitative Research | 2 | 2020 | 291 | 0.190 |
Why?
|
| Food Quality | 1 | 2020 | 1 | 0.190 |
Why?
|
| Catheter Ablation | 1 | 2023 | 252 | 0.190 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2020 | 21 | 0.190 |
Why?
|
| Adiponectin | 1 | 2020 | 20 | 0.180 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2020 | 22 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 1363 | 0.180 |
Why?
|
| ras Proteins | 2 | 2011 | 130 | 0.180 |
Why?
|
| Coordination Complexes | 1 | 2020 | 20 | 0.180 |
Why?
|
| Biomarkers, Tumor | 3 | 2018 | 1543 | 0.180 |
Why?
|
| Death | 1 | 2021 | 85 | 0.180 |
Why?
|
| Kidney Neoplasms | 1 | 2006 | 635 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 285 | 0.180 |
Why?
|
| Pharmacists | 1 | 2020 | 32 | 0.180 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2020 | 114 | 0.170 |
Why?
|
| Metastasectomy | 1 | 2019 | 9 | 0.170 |
Why?
|
| Nigeria | 1 | 2020 | 156 | 0.170 |
Why?
|
| Adaptation, Psychological | 1 | 2020 | 166 | 0.170 |
Why?
|
| Drug Prescriptions | 2 | 2018 | 144 | 0.170 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2013 | 599 | 0.160 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 207 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 257 | 0.160 |
Why?
|
| Self Efficacy | 1 | 2019 | 54 | 0.160 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 29 | 0.160 |
Why?
|
| Drug Administration Schedule | 5 | 2020 | 894 | 0.160 |
Why?
|
| Organ Preservation | 3 | 2024 | 105 | 0.160 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 330 | 0.160 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2015 | 35 | 0.160 |
Why?
|
| Leukemia | 1 | 2020 | 323 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 195 | 0.160 |
Why?
|
| Hematology | 1 | 2018 | 30 | 0.150 |
Why?
|
| Intestinal Obstruction | 1 | 2018 | 88 | 0.150 |
Why?
|
| Salvage Therapy | 2 | 2017 | 235 | 0.150 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 2347 | 0.150 |
Why?
|
| Radiosurgery | 1 | 2021 | 280 | 0.150 |
Why?
|
| Residence Characteristics | 1 | 2019 | 200 | 0.150 |
Why?
|
| Rectum | 1 | 2018 | 148 | 0.150 |
Why?
|
| Delayed Diagnosis | 1 | 2017 | 32 | 0.150 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 25 | 0.150 |
Why?
|
| Quality of Life | 3 | 2021 | 1662 | 0.140 |
Why?
|
| Cost Savings | 2 | 2014 | 69 | 0.140 |
Why?
|
| Sirolimus | 1 | 2018 | 170 | 0.140 |
Why?
|
| Attitude to Health | 1 | 2018 | 222 | 0.140 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2017 | 105 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2017 | 112 | 0.140 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 2016 | 29 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2019 | 833 | 0.140 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 148 | 0.130 |
Why?
|
| Exercise | 1 | 2019 | 322 | 0.130 |
Why?
|
| Pyrimidines | 2 | 2011 | 372 | 0.130 |
Why?
|
| Age Factors | 3 | 2019 | 1867 | 0.130 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 705 | 0.130 |
Why?
|
| Drug Therapy | 1 | 2016 | 70 | 0.130 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 824 | 0.130 |
Why?
|
| Physician's Role | 1 | 2017 | 177 | 0.130 |
Why?
|
| Educational Status | 1 | 2016 | 194 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2017 | 616 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 85 | 0.130 |
Why?
|
| Collagen Type I | 1 | 2015 | 72 | 0.130 |
Why?
|
| Episode of Care | 1 | 2014 | 7 | 0.120 |
Why?
|
| Choice Behavior | 1 | 2016 | 160 | 0.120 |
Why?
|
| Chemoradiotherapy | 3 | 2023 | 309 | 0.120 |
Why?
|
| Commerce | 1 | 2014 | 31 | 0.120 |
Why?
|
| Colon | 1 | 2018 | 509 | 0.120 |
Why?
|
| Politics | 1 | 2015 | 52 | 0.120 |
Why?
|
| Genetic Testing | 2 | 2018 | 537 | 0.120 |
Why?
|
| Specialization | 1 | 2015 | 65 | 0.120 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2016 | 244 | 0.120 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2017 | 223 | 0.120 |
Why?
|
| Health Insurance Exchanges | 1 | 2014 | 2 | 0.120 |
Why?
|
| Social Support | 1 | 2016 | 208 | 0.120 |
Why?
|
| Primary Prevention | 1 | 2014 | 81 | 0.120 |
Why?
|
| Logistic Models | 3 | 2019 | 1212 | 0.120 |
Why?
|
| Research Design | 1 | 2017 | 597 | 0.110 |
Why?
|
| Eligibility Determination | 1 | 2014 | 36 | 0.110 |
Why?
|
| Policy Making | 1 | 2014 | 62 | 0.110 |
Why?
|
| Time Factors | 5 | 2019 | 5320 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 1043 | 0.110 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2011 | 164 | 0.110 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 2 | 2023 | 18 | 0.110 |
Why?
|
| Delaware | 1 | 2013 | 2 | 0.110 |
Why?
|
| Infusions, Intravenous | 3 | 2020 | 434 | 0.110 |
Why?
|
| Comorbidity | 2 | 2022 | 948 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 364 | 0.110 |
Why?
|
| New York | 1 | 2013 | 72 | 0.110 |
Why?
|
| Off-Label Use | 1 | 2012 | 16 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 84 | 0.110 |
Why?
|
| Insurance Coverage | 1 | 2014 | 118 | 0.110 |
Why?
|
| Maximum Tolerated Dose | 3 | 2019 | 272 | 0.110 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2023 | 40 | 0.110 |
Why?
|
| Paclitaxel | 2 | 2019 | 479 | 0.100 |
Why?
|
| Patents as Topic | 1 | 2012 | 12 | 0.100 |
Why?
|
| Geriatric Assessment | 1 | 2013 | 182 | 0.100 |
Why?
|
| Attitude of Health Personnel | 2 | 2016 | 643 | 0.100 |
Why?
|
| Life Style | 1 | 2013 | 172 | 0.100 |
Why?
|
| Genomics | 1 | 2017 | 761 | 0.100 |
Why?
|
| Peptides | 1 | 2015 | 647 | 0.100 |
Why?
|
| Alanine | 1 | 2012 | 83 | 0.100 |
Why?
|
| Triazines | 1 | 2012 | 53 | 0.100 |
Why?
|
| Chromosomal Instability | 1 | 2011 | 19 | 0.100 |
Why?
|
| Ploidies | 1 | 2011 | 41 | 0.100 |
Why?
|
| Young Adult | 4 | 2018 | 6289 | 0.090 |
Why?
|
| Cost Sharing | 1 | 2011 | 17 | 0.090 |
Why?
|
| Loss of Heterozygosity | 1 | 2011 | 86 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 1067 | 0.090 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 71 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2011 | 146 | 0.090 |
Why?
|
| Thiazoles | 1 | 2011 | 128 | 0.090 |
Why?
|
| Vitamin D | 1 | 2013 | 268 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 1096 | 0.090 |
Why?
|
| Pilot Projects | 3 | 2018 | 865 | 0.090 |
Why?
|
| Statistics as Topic | 1 | 2010 | 234 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2020 | 988 | 0.080 |
Why?
|
| Genotype | 3 | 2020 | 1848 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2018 | 485 | 0.080 |
Why?
|
| Disease Progression | 3 | 2019 | 1488 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 783 | 0.080 |
Why?
|
| Microsatellite Instability | 2 | 2024 | 49 | 0.080 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2020 | 58 | 0.080 |
Why?
|
| Positron-Emission Tomography | 2 | 2020 | 336 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 155 | 0.080 |
Why?
|
| ErbB Receptors | 1 | 2011 | 500 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2019 | 1768 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2008 | 287 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2012 | 390 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2399 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2009 | 771 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 1715 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 604 | 0.070 |
Why?
|
| Sex Factors | 2 | 2021 | 1063 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 277 | 0.070 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2006 | 67 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2022 | 682 | 0.070 |
Why?
|
| Canada | 2 | 2017 | 208 | 0.070 |
Why?
|
| Imatinib Mesylate | 1 | 2006 | 127 | 0.070 |
Why?
|
| Health Care Surveys | 2 | 2020 | 280 | 0.060 |
Why?
|
| Patient Safety | 2 | 2019 | 216 | 0.060 |
Why?
|
| Interferon-alpha | 1 | 2006 | 226 | 0.060 |
Why?
|
| Benzamides | 1 | 2006 | 237 | 0.060 |
Why?
|
| Culture | 1 | 2005 | 53 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2006 | 590 | 0.060 |
Why?
|
| Age Distribution | 1 | 2005 | 200 | 0.060 |
Why?
|
| Piperazines | 1 | 2006 | 283 | 0.060 |
Why?
|
| DNA Mismatch Repair | 1 | 2024 | 55 | 0.060 |
Why?
|
| Patient Selection | 2 | 2018 | 682 | 0.060 |
Why?
|
| Microwaves | 1 | 2023 | 36 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 1940 | 0.060 |
Why?
|
| Advance Directives | 1 | 2023 | 64 | 0.060 |
Why?
|
| Peritoneum | 1 | 2023 | 57 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2019 | 2291 | 0.050 |
Why?
|
| Hepatectomy | 1 | 2023 | 170 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2009 | 1063 | 0.050 |
Why?
|
| Monoterpenes | 1 | 2022 | 5 | 0.050 |
Why?
|
| GPI-Linked Proteins | 1 | 2022 | 51 | 0.050 |
Why?
|
| Celecoxib | 1 | 2022 | 31 | 0.050 |
Why?
|
| Disease Management | 1 | 2024 | 329 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 267 | 0.050 |
Why?
|
| Dietary Fats | 1 | 2022 | 135 | 0.050 |
Why?
|
| Physician-Patient Relations | 2 | 2020 | 625 | 0.050 |
Why?
|
| Occult Blood | 1 | 2021 | 17 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2022 | 202 | 0.050 |
Why?
|
| Cause of Death | 1 | 2022 | 266 | 0.050 |
Why?
|
| Gastrectomy | 1 | 2021 | 69 | 0.050 |
Why?
|
| C-Peptide | 1 | 2020 | 179 | 0.040 |
Why?
|
| Illinois | 1 | 2021 | 472 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2020 | 225 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 412 | 0.040 |
Why?
|
| Obesity | 1 | 2006 | 966 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2015 | 684 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 948 | 0.040 |
Why?
|
| Organometallic Compounds | 1 | 2020 | 134 | 0.040 |
Why?
|
| Diet | 1 | 2022 | 442 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2021 | 279 | 0.040 |
Why?
|
| Albumins | 1 | 2019 | 129 | 0.040 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2018 | 6 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 172 | 0.040 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2019 | 33 | 0.040 |
Why?
|
| Telemedicine | 1 | 2021 | 185 | 0.040 |
Why?
|
| Markov Chains | 1 | 2019 | 127 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 84 | 0.040 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2018 | 46 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2019 | 142 | 0.040 |
Why?
|
| Filgrastim | 1 | 2017 | 57 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 69 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2018 | 306 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2017 | 41 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 207 | 0.040 |
Why?
|
| Genes, ras | 1 | 2017 | 98 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2018 | 185 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 540 | 0.040 |
Why?
|
| Hospitals | 1 | 2019 | 299 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 576 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 229 | 0.030 |
Why?
|
| Stakeholder Participation | 1 | 2016 | 22 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 385 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2016 | 88 | 0.030 |
Why?
|
| Snake Venoms | 1 | 2015 | 10 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2018 | 1130 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 69 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2016 | 147 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 344 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 358 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2017 | 396 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 502 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2018 | 341 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 294 | 0.030 |
Why?
|
| Pyrroles | 1 | 2015 | 187 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 94 | 0.030 |
Why?
|
| Haplotypes | 1 | 2016 | 637 | 0.030 |
Why?
|
| Indoles | 1 | 2015 | 312 | 0.030 |
Why?
|
| Remission Induction | 1 | 2015 | 740 | 0.030 |
Why?
|
| Insurance Claim Review | 1 | 2012 | 45 | 0.030 |
Why?
|
| Health Services for the Aged | 1 | 2012 | 32 | 0.030 |
Why?
|
| Appetite | 1 | 2012 | 26 | 0.030 |
Why?
|
| Collagen Type IV | 1 | 2012 | 26 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 2012 | 43 | 0.020 |
Why?
|
| Self Report | 1 | 2013 | 295 | 0.020 |
Why?
|
| Adolescent | 2 | 2018 | 9237 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2012 | 238 | 0.020 |
Why?
|
| Dasatinib | 1 | 2011 | 37 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2011 | 76 | 0.020 |
Why?
|
| Fatigue | 1 | 2012 | 179 | 0.020 |
Why?
|
| Nausea | 1 | 2012 | 176 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2011 | 529 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 1140 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2010 | 575 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 1706 | 0.020 |
Why?
|
| Hypertension | 1 | 2012 | 741 | 0.020 |
Why?
|
| Animals | 1 | 2022 | 27324 | 0.010 |
Why?
|